Search

Displaying results 1261 - 1270 of 1915 in total
  1. Drug

    Mesalazine

    go.drugbank.com/drugs/DB00244
    ApprovedInvestigational

    An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and main...

  2. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).

  3. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Folika-NC
  4. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles i...

    Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Products: VIRAFERON INYECTABLE 3 MILLONES IU
  5. Drug

    Choline salicylate

    go.drugbank.com/drugs/DB14006
    ApprovedNutraceutical

    Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers [L2134].

  6. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.

  7. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

  8. Drug

    ALKS 27

    go.drugbank.com/drugs/DB05752
    Experimental

    Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.

  9. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate.

    Mixtures: LEVOCAENT-NX 100/25/200, LEVOCAENT-NX 100/25/200
  10. Drug

    Metronidazole benzoate

    go.drugbank.com/drugs/DB15759
    Investigational

    Mixtures: DIARSET NX- M SUSPENSION, AMEBICOL NF SUSPENSION